Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) will present multiple data sets on its 68Ga-Trivehexin (RAD 301) technology during the European Molecular Imaging Meeting (EMIM) from March 12-15, 2024, in Porto, Portugal.
EMIM attracts more than 1,000 international participants where the latest developments in morphological, functional and molecular imaging are presented, including new strategies for image-guided therapies and theranostics.
Dr Johannes Notni, chief scientific officer of TRIMT GmbH and a member of Radiopharm’s Scientific Advisory Board, will attend the meeting alongside several colleagues to deliver a series of presentations on RAD 301, including:
- ‘Efficient reduction of renal uptake of αvβ6-integrin targeted at Ga-68 PET imaging agents and Lu-177 therapeutics’;
- ‘Preliminary results of a Phase 2 study: 68Ga-Trivehexin PET/CT of αvβ6-integrin expression in HNSCC and PDAC and correlation with ITGB6 expression’; and
- ‘Relevance of αvβ6-integrin as a theranostic target: In-depth immuno-histochemistry analysis of membranous ITGB6 expression in various human cancers’.
Trivehexin is a peptide-based molecule that targets αvβ6-integrin, a cellular marker for tumour invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target.
Radiopharm recently dosed the first participant in a Phase I clinical trial for RAD 301 being conducted at the Montefiore Medical Center, Albert Eistein College of Medicine, NY, USA. The study will assess the safety, radiation dosimetry and imaging characteristics of RAD 301 in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC).